TiGenix : to Present at Key Conferences H1 2013
TiGenix to Present at Key Conferences H1 2013
(firmenpresse) - LEUVEN, BELGIUM -- (Marketwire) -- 02/04/13 -- TiGenix (EURONEXT BRUSSELS: TIG), a leader in the field of cell therapy, announced today that during the first half of 2013 the company will present at a number of key events in Europe and the U.S. geared at investor, industry, and academic audiences to highlight the commercial potential of ChondroCelect®, the only approved cell therapy in Europe, and of the company's innovative proprietary allogeneic stem cell platform with programs in Phase II, and III for respectively the treatment of rheumatoid arthritis (Cx611) and perianal fistulas in Crohn's disease (Cx601).
February 11-12
, The Waldorf Astoria, New York, NY, U.S.
Presenter: Eduardo Bravo, CEO
Date & time: Tuesday, February 12, 8:30 - 8:55
Room: Room Conrad
(registration free, but required)
Replay available 1 hour after live event; archived webcast expires May 12, 2013
February 19
, Battery Gardens, Battery Park, New York, NY, U.S.
Presenter: Eduardo Bravo, CEO
Date & time: Tuesday, February 19, 11:55 - 12:18
March 11-13
, Centre Convencions Internacional, Barcelona, Spain
Attendees: Eduardo Bravo, CEO, Claudia Jiménez, Senior Director Corporate Development
March 16
, KBC Tower, Ghent, Belgium
Presenter: Eduardo Bravo, CEO
March 19
, Brussels, Belgium
Attendees: Eduardo Bravo, CEO, Claudia D'Augusta, CFO
March 23
, KBC Private Banking, Leuven, Belgium
Presenter: Wilfried Dalemans, CTO
Location: Archipel Business Center
Date & time: Saturday, March 23, 11:45 - 12:30
April 15-16
Paris, France
Attendees: Eduardo Bravo, CEO, Claudia D'Augusta, CFO
April 17
, The Grand, Amsterdam, the Netherlands
Presenter: Claudia D'Augusta, CFO
April 17
, New York, NY, U.S.
Presenter: Eduardo Bravo, CEO
April 22-25
, McCormick Place, Chicago, Illinois, U.S.
Attendee: Claudia Jimenez, Senior Director Corporate Development
April 23
, Amsterdam, the Netherlands
Attendee: Claudia D'Augusta, CFO
May 21-23
, Victoria Plaza, London, UK.
Presenter: Eduardo Bravo, CEO
Date & time: Tuesday, May 21, 10:05 - 10:30
Title: Commercial financing: exploiting translational funding opportunities
May 22-23
, Stockholm, Sweden
Presenter: Eduardo Bravo, CEO
May 30
, ICC Ghent, Belgium
Attendee: Wilfried Dalemans, CTO
About TiGenix
TiGenix NV (EURONEXT BRUSSELS: TIG) is a leading European cell therapy company with a marketed product for cartilage repair, ChondroCelect®, and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands). For more information please visit .
This document may contain forward-looking statements and estimates with respect to the anticipated future performance of TiGenix and the market in which it operates. Certain of these statements, forecasts and estimates can be recognised by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will" and "continue" and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond TiGenix' control. Therefore, actual results, the financial condition, performance or achievements of TiGenix, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this document. TiGenix disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in TiGenix' expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by Belgian law.
Eduardo Bravo
Chief Executive Officer
Claudia D'Augusta
Chief Financial Officer
Hans Herklots
+32 16 39 60 97
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 04.02.2013 - 07:52 Uhr
Sprache: Deutsch
News-ID 225662
Anzahl Zeichen: 0
contact information:
Town:
LEUVEN, BELGIUM
Kategorie:
Alternative
Diese Pressemitteilung wurde bisher 251 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"TiGenix : to Present at Key Conferences H1 2013"
steht unter der journalistisch-redaktionellen Verantwortung von
TiGenix (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
